Figure 4.
High MET-expressing BxPC3 and low MET-expressing MIA PaCa 2 tumors were treated with a fractionation schedule 9.25 MBq/20 µg of [177Lu]Lu-DTPA-Onartuzumab. The fractionated schedule showed therapeutic efficacy for both high and low MET expressing tumors compared to saline and non-labeled onartuzumab controls. Adapted with permission from Escorcia et al., Theranostics, made available under a Creative Commons CC-BY license.